Cargando…
Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer
SIMPLE SUMMARY: Pancreatic cancer is one of the most heterogeneous and aggressive tumours that exist. The median survival of diagnosed patients is limited. For all these reasons, it is necessary to develop new disease markers that allow guidelines for clinical action to improve the average survival...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029823/ https://www.ncbi.nlm.nih.gov/pubmed/35454771 http://dx.doi.org/10.3390/cancers14081866 |
_version_ | 1784691994144014336 |
---|---|
author | Pekarek, Leonel Fraile-Martinez, Oscar Garcia-Montero, Cielo Saez, Miguel A. Barquero-Pozanco, Ines del Hierro-Marlasca, Laura de Castro Martinez, Patricia Romero-Bazán, Adoración Alvarez-Mon, Miguel A. Monserrat, Jorge García-Honduvilla, Natalio Buján, Julia Alvarez-Mon, Melchor Guijarro, Luis G. Ortega, Miguel A. |
author_facet | Pekarek, Leonel Fraile-Martinez, Oscar Garcia-Montero, Cielo Saez, Miguel A. Barquero-Pozanco, Ines del Hierro-Marlasca, Laura de Castro Martinez, Patricia Romero-Bazán, Adoración Alvarez-Mon, Miguel A. Monserrat, Jorge García-Honduvilla, Natalio Buján, Julia Alvarez-Mon, Melchor Guijarro, Luis G. Ortega, Miguel A. |
author_sort | Pekarek, Leonel |
collection | PubMed |
description | SIMPLE SUMMARY: Pancreatic cancer is one of the most heterogeneous and aggressive tumours that exist. The median survival of diagnosed patients is limited. For all these reasons, it is necessary to develop new disease markers that allow guidelines for clinical action to improve the average survival of patients with pancreatic cancer. ABSTRACT: The incidence and prevalence of pancreatic adenocarcinoma have increased in recent years. Pancreatic cancer is the seventh leading cause of cancer death, but it is projected to become the second leading cause of cancer-related mortality by 2040. Most patients are diagnosed in an advanced stage of the disease, with very limited 5-year survival. The discovery of different tissue markers has elucidated the underlying pathophysiology of pancreatic adenocarcinoma and allowed stratification of patient risk at different stages and assessment of tumour recurrence. Due to the invasive capacity of this tumour and the absence of screening markers, new immunohistochemical and serological markers may be used as prognostic markers for recurrence and in the study of possible new therapeutic targets because the survival of these patients is low in most cases. The present article reviews the currently used main histopathological and serological markers and discusses the main characteristics of markers under development. |
format | Online Article Text |
id | pubmed-9029823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90298232022-04-23 Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer Pekarek, Leonel Fraile-Martinez, Oscar Garcia-Montero, Cielo Saez, Miguel A. Barquero-Pozanco, Ines del Hierro-Marlasca, Laura de Castro Martinez, Patricia Romero-Bazán, Adoración Alvarez-Mon, Miguel A. Monserrat, Jorge García-Honduvilla, Natalio Buján, Julia Alvarez-Mon, Melchor Guijarro, Luis G. Ortega, Miguel A. Cancers (Basel) Review SIMPLE SUMMARY: Pancreatic cancer is one of the most heterogeneous and aggressive tumours that exist. The median survival of diagnosed patients is limited. For all these reasons, it is necessary to develop new disease markers that allow guidelines for clinical action to improve the average survival of patients with pancreatic cancer. ABSTRACT: The incidence and prevalence of pancreatic adenocarcinoma have increased in recent years. Pancreatic cancer is the seventh leading cause of cancer death, but it is projected to become the second leading cause of cancer-related mortality by 2040. Most patients are diagnosed in an advanced stage of the disease, with very limited 5-year survival. The discovery of different tissue markers has elucidated the underlying pathophysiology of pancreatic adenocarcinoma and allowed stratification of patient risk at different stages and assessment of tumour recurrence. Due to the invasive capacity of this tumour and the absence of screening markers, new immunohistochemical and serological markers may be used as prognostic markers for recurrence and in the study of possible new therapeutic targets because the survival of these patients is low in most cases. The present article reviews the currently used main histopathological and serological markers and discusses the main characteristics of markers under development. MDPI 2022-04-07 /pmc/articles/PMC9029823/ /pubmed/35454771 http://dx.doi.org/10.3390/cancers14081866 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pekarek, Leonel Fraile-Martinez, Oscar Garcia-Montero, Cielo Saez, Miguel A. Barquero-Pozanco, Ines del Hierro-Marlasca, Laura de Castro Martinez, Patricia Romero-Bazán, Adoración Alvarez-Mon, Miguel A. Monserrat, Jorge García-Honduvilla, Natalio Buján, Julia Alvarez-Mon, Melchor Guijarro, Luis G. Ortega, Miguel A. Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer |
title | Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer |
title_full | Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer |
title_fullStr | Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer |
title_full_unstemmed | Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer |
title_short | Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer |
title_sort | clinical applications of classical and novel biological markers of pancreatic cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029823/ https://www.ncbi.nlm.nih.gov/pubmed/35454771 http://dx.doi.org/10.3390/cancers14081866 |
work_keys_str_mv | AT pekarekleonel clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT frailemartinezoscar clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT garciamonterocielo clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT saezmiguela clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT barqueropozancoines clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT delhierromarlascalaura clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT decastromartinezpatricia clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT romerobazanadoracion clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT alvarezmonmiguela clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT monserratjorge clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT garciahonduvillanatalio clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT bujanjulia clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT alvarezmonmelchor clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT guijarroluisg clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer AT ortegamiguela clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer |